Biomemory key facts
- Developer of data storage drives designed to offer bio-digital data storage for large companies and administrations.
- Biomemory’s last known valuation is $38.5M.
- It has raised $23.4M; the latest was Early Stage VC ($18.0M) in Nov 2024.
- Notable investors include Bpifrance, Agoranov, Crédit Mutuel Equity, AH Capital, ADNEXUS (Paris) — 17 tracked in total.
- Status: Privately Held (backing).
Who backs Biomemory
17+Membership and data by Private Market View
- ·The complete investor list: 17 names
- ·Watch Biomemory: the Monday email on marks, rounds and moves
Biomemory funding rounds
No funding rounds for Biomemory are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Biomemory valuation
Biomemory's last known valuation is $38.5 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Biomemory investors
17 investors are on record for Biomemory, including Bpifrance, Agoranov, Crédit Mutuel Equity and AH Capital.
About Biomemory
Developer of data storage drives designed to offer bio-digital data storage for large companies and administrations. The company's drives are low-cost and have a biobased system for storing large amounts of computer data on long DNA strands than any SSD or magnetic tape that is stable at ambient temperature with no energetic input and CO2 emission, enabling researchers to get ultimate storage media durable for thousands of years.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2021
- Employees
- 33
- Website
- biomemory.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Biomemory’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.